Biogen Buys Rights to Experimental Alzheimer’s Drugs

Biogen Idec Inc., maker of the multiple sclerosis drugs Avonex, Tysabri and Tecfidera, bought rights to Japan’s Eisai Co.’s experimental Alzheimer’s disease medicines as it seeks to add treatments for brain disorders. Biogen will pay Eisai an upfront payment, and a fixed amount of development and milestones as the drugs...
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news